The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2021 | Phase III MF studies evaluating parsaclisib + ruxolitinib in treatment naive & suboptimal responders
Abdulraheem Yacoub, MD, The University of Kansas Health System, Fairway, KA, details the rationale of two Phase III studies evaluating parsaclisib in patients with myelofibrosis (MF). The first study discussed by Dr Yacoub investigates the use of parsaclisib plus ruxolitinib in patients with myelofibrosis who have previously had suboptimal responses to ruxolitinib. The second study discussed tests this combination in patients with myelofibrosis who are JAK- and PI3K-inhibitor treatment-naive. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
